{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:37:28Z","timestamp":1793288248912,"version":"4.5.0"},"reference-count":60,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"name":"the Natural Science Foundation of Shanghai","award":["22ZR1479200"],"award-info":[{"award-number":["22ZR1479200"]}]},{"name":"the Shanghai Key Laboratory of Breast Cancer","award":["12DZ2260100"],"award-info":[{"award-number":["12DZ2260100"]}]},{"name":"Youth Talent Program of Shanghai Health Commission","award":["2022YQ012"],"award-info":[{"award-number":["2022YQ012"]}]},{"name":"the SHDC Municipal Project for Developing Emerging and Frontier Technology in Shanghai Hospitals","award":["SHDC12021103"],"award-info":[{"award-number":["SHDC12021103"]}]},{"name":"the Clinical Research Plan of SHDC","award":["SHDC2020CR4002"],"award-info":[{"award-number":["SHDC2020CR4002"]}]},{"name":"the Clinical Research Plan of SHDC","award":["SHDC2020CR5005"],"award-info":[{"award-number":["SHDC2020CR5005"]}]},{"name":"the National Key Research and Development Project of China","award":["2020YFA0112304"],"award-info":[{"award-number":["2020YFA0112304"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["91959207"],"award-info":[{"award-number":["91959207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["92159301"],"award-info":[{"award-number":["92159301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Program of Shanghai Academic\/Technology Research Leader","award":["20XD1421100"],"award-info":[{"award-number":["20XD1421100"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with unfavorable outcomes. Developing therapeutic targets for TNBC remains a challenge. Here, we identified that acetyl-CoA acyltransferase 1 (ACAA1) is highly expressed in the luminal androgen receptor (LAR) subtype of TNBC compared with adjacent normal tissues in our TNBC proteomics dataset. Inhibition of ACAA1 restrained TNBC proliferation and potentiated the response to the cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitor abemaciclib. Mechanistically, ACAA1 interacted with CDK4, and the inhibition of ACAA1 blocked RB transcriptional corepressor 1 (RB1) phosphorylation, resulting in G1\u2013S cell-cycle arrest. Importantly, trimetazidine, a traditional drug for ischemic heart disease, caused a decrease in ACAA1 protein levels and enhanced the efficacy of abemaciclib in preclinical TNBC models. In conclusion, this study identifies that ACAA1 is a therapeutic target in TNBC and suggests the combination of trimetazidine and abemaciclib could be beneficial for ACAA1-high TNBCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>ACAA1 is highly expressed in TNBC, serving as a potential therapeutic target in ACAA1-high tumors and a predictive biomarker of resistance to CDK4\/6 inhibitors for RB1-proficient patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-22-2143","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T11:50:00Z","timestamp":1683028200000},"page":"1711-1724","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4\/6 Inhibitors in Triple-Negative Breast Cancer"],"prefix":"10.1158","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-4263","authenticated-orcid":false,"given":"Wen-Ting","family":"Peng","sequence":"first","affiliation":[{"name":"1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China."},{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China."},{"name":"3The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-1323","authenticated-orcid":false,"given":"Xi","family":"Jin","sequence":"additional","affiliation":[{"name":"1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China."},{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-305X","authenticated-orcid":false,"given":"Xiao-En","family":"Xu","sequence":"additional","affiliation":[{"name":"1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China."},{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8067-9567","authenticated-orcid":false,"given":"Yun-Song","family":"Yang","sequence":"additional","affiliation":[{"name":"1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China."},{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4890-6424","authenticated-orcid":false,"given":"Ding","family":"Ma","sequence":"additional","affiliation":[{"name":"1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China."},{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-148X","authenticated-orcid":false,"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[{"name":"1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China."},{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3699-2630","authenticated-orcid":false,"given":"Yi-Zhou","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China."},{"name":"2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"2025112417463122700_bib1","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2025112417463122700_bib2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"2025112417463122700_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112417463122700_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2025112417463122700_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2025112417463122700_bib6","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025112417463122700_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112417463122700_bib8","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"2025112417463122700_bib9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"2025112417463122700_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"2025112417463122700_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112417463122700_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"2025112417463122700_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial","volume":"31","author":"Jiang","year":"2021","journal-title":"Cell Res"},{"key":"2025112417463122700_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas N","year":"2012","journal-title":"Nature"},{"key":"2025112417463122700_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-009-0460-8","article-title":"Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines","volume":"121","author":"Hollestelle","year":"2010","journal-title":"Breast Cancer Res Tr"},{"key":"2025112417463122700_bib16","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025112417463122700_bib17","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.2147\/CMAR.S310649","article-title":"Potential prospect of CDK4\/6 inhibitors in triple-negative breast cancer","volume":"13","author":"Hu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"2025112417463122700_bib18","doi-asserted-by":"crossref","first-page":"110460","DOI":"10.1016\/j.celrep.2022.110460","article-title":"Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer","volume":"38","author":"Gong","year":"2022","journal-title":"Cell Rep"},{"key":"2025112417463122700_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"key":"2025112417463122700_bib20","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","article-title":"Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer","volume":"19","author":"Gyorffy","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"2025112417463122700_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13073-018-0602-x","article-title":"Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival","volume":"10","author":"Tang","year":"2018","journal-title":"Genome Med"},{"key":"2025112417463122700_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"2025112417463122700_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2025112417463122700_bib24","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/0008-5472.CAN-18-3418","article-title":"Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res"},{"key":"2025112417463122700_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s13046-019-1411-9","article-title":"SCP2-mediated cholesterol membrane trafficking promotes the growth of pituitary adenomas via Hedgehog signaling activation","volume":"38","author":"Ding","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2025112417463122700_bib26","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"2025112417463122700_bib27","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1101\/gad.282145.116","article-title":"RB1: a prototype tumor suppressor and an enigma","volume":"30","author":"Dyson","year":"2016","journal-title":"Genes Dev"},{"key":"2025112417463122700_bib28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"2025112417463122700_bib29","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1038\/sj.onc.1210191","article-title":"The ubiquitin\u2013proteasome system regulates p53-mediated transcription at p21waf1 promoter","volume":"26","author":"Zhu","year":"2007","journal-title":"Oncogene"},{"key":"2025112417463122700_bib30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"key":"2025112417463122700_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.semcdb.2010.02.005","article-title":"Chaperone-mediated autophagy: molecular mechanisms and physiological relevance","volume":"21","author":"Orenstein","year":"2010","journal-title":"Semin Cell Dev Biol"},{"key":"2025112417463122700_bib32","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1073\/pnas.79.6.1889","article-title":"3-Methyladenine: specific inhibitor of autophagic\/lysosomal protein degradation in isolated rat hepatocytes","volume":"79","author":"Seglen","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112417463122700_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.physiol.61.1.243","article-title":"Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology","volume":"61","author":"Feder","year":"1999","journal-title":"Annu Rev Physiol"},{"key":"2025112417463122700_bib34","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: a key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes Cancer"},{"key":"2025112417463122700_bib35","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1073\/pnas.0809645106","article-title":"Crystal structure of human CDK4 in complex with a D-type cyclin","volume":"106","author":"Day","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112417463122700_bib36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/cells8040321","article-title":"Updates on the CDK4\/6 inhibitory strategy and combinations in breast cancer","volume":"8","author":"Sobhani","year":"2019","journal-title":"Cells"},{"key":"2025112417463122700_bib37","doi-asserted-by":"crossref","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","article-title":"Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance","volume":"25","author":"Zhao","year":"2020","journal-title":"Oncologist"},{"key":"2025112417463122700_bib38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2025112417463122700_bib39","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025112417463122700_bib40","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1073\/pnas.84.8.2494","article-title":"Human peroxisomal 3-oxoacyl-coenzyme A thiolase deficiency","volume":"84","author":"Schram","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112417463122700_bib41","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/ijc.25901","article-title":"Molecular markers of endometrial carcinoma detected in uterine aspirates","volume":"129","author":"Colas","year":"2011","journal-title":"Int J Cancer"},{"key":"2025112417463122700_bib42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.prp.2017.01.019","article-title":"Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence","volume":"213","author":"Yan","year":"2017","journal-title":"Pathol Res Pract"},{"key":"2025112417463122700_bib43","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-480136\/v1","article-title":"25-hydroxycholesterol regulates migration, invasion and EMT of colorectal cancer through miR-92a-3p\/ACAA1\/NF-\u03baB Pathway","author":"Wang","year":"2021"},{"key":"2025112417463122700_bib44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7150\/ijms.48123","article-title":"Upregulation of peroxisome proliferator-activated receptor-alpha and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer","volume":"18","author":"Wang","year":"2021","journal-title":"Int J Med Sci"},{"key":"2025112417463122700_bib45","article-title":"Abstract# 3945: Genetic variation in estrogen esterification pathway genes ACAA1, ACAA2, and LCAT and breast cancer risk","author":"Deming","year":"2009"},{"key":"2025112417463122700_bib46","doi-asserted-by":"crossref","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: From basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"2025112417463122700_bib47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41568-018-0008-5","article-title":"Non-canonical functions of the RB protein in cancer","volume":"18","author":"Dick","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2025112417463122700_bib48","doi-asserted-by":"crossref","first-page":"15916","DOI":"10.1038\/ncomms15916","article-title":"CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers","volume":"8","author":"Vijayaraghavan","year":"2017","journal-title":"Nat Commun"},{"key":"2025112417463122700_bib49","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4161\/cc.21195","article-title":"Therapeutic response to CDK4\/6 inhibition in breast cancer defined by ex vivo analyses of human tumors","volume":"11","author":"Dean","year":"2012","journal-title":"Cell Cycle"},{"key":"2025112417463122700_bib50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"2025112417463122700_bib51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2025112417463122700_bib52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2025112417463122700_bib53","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-20-0807","article-title":"Activity of combined androgen receptor antagonism and cell cycle inhibition in androgen receptor positive triple negative breast cancer","volume":"20","author":"Christenson","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2025112417463122700_bib54","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1038\/s41467-020-16170-3","article-title":"Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer","volume":"11","author":"Ge","year":"2020","journal-title":"Nat Commun"},{"key":"2025112417463122700_bib55","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1038\/s41467-019-10743-7","article-title":"Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer","volume":"10","author":"Ni","year":"2019","journal-title":"Nat Commun"},{"key":"2025112417463122700_bib56","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1158\/1078-0432.CCR-18-1880","article-title":"Expression of MT4-MMP, EGFR, and RB in triple-negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy","volume":"25","author":"Foidart","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025112417463122700_bib57","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1158\/0008-5472.CAN-17-2210","article-title":"Combined CDK4\/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple-negative breast cancer","volume":"77","author":"Teo","year":"2017","journal-title":"Cancer Res"},{"key":"2025112417463122700_bib58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003495-199958010-00016","article-title":"Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions","volume":"58","author":"McClellan","year":"1999","journal-title":"Drugs"},{"key":"2025112417463122700_bib59","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.febslet.2005.01.082","article-title":"Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists","volume":"579","author":"Andela","year":"2005","journal-title":"FEBS Lett"},{"key":"2025112417463122700_bib60","doi-asserted-by":"crossref","first-page":"101632","DOI":"10.1016\/j.clinre.2021.101632","article-title":"Trimetazidine alone or in combination with gemcitabine and\/or abraxane decreased cell viability, migration and ATP levels and induced apoptosis of human pancreatic cells","volume":"45","author":"Atli Sekeroglu","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-2143\/3328002\/can-22-2143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/10\/1711\/3329718\/1711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/10\/1711\/3329718\/1711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:46:52Z","timestamp":1764024412000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/83\/10\/1711\/726295\/Inhibition-of-ACAA1-Restrains-Proliferation-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5,2]]},"published-print":{"date-parts":[[2023,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-22-2143","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6626689.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6626689.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22732543","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22820305","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6626689","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22820305.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22732543.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.30700120","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}